Price CAGR:-52.14%(TTM)
Over the latest trailing 12-month period, price cagr is -52.14%. The comparable SPY value is +20.86%. Year-to-date price return is -47.38%. Price CAGR uses adjusted close price history and excludes dividends.
Over longer horizons, Price CAGR averages -19.71% over 3 years and -11.68% over 5 years. The price CAGR (Compound Annual Growth Rate) shows how the company's stock price has grown over various time periods. This measures pure price appreciation without including dividends.
PODD Price CAGR Chart
Insulet Corp. (PODD)
PODD Quarterly Price (YoY)
Price growth vs the same quarter one year earlier, last 20 quarters.
PODD Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 321.36 | 146.01 | -175.35 | -54.56% | -54.56% |
| 2025 | 182.79 | 321.36 | +138.57 | +75.81% | +75.81% |
| 2024 | 301.03 | 182.79 | -118.24 | -39.28% | -39.28% |
| 2023 | 190.03 | 301.03 | +111.00 | +58.41% | +58.41% |
| 2022 | 239.79 | 190.03 | -49.76 | -20.75% | -20.75% |
| 2021 | 195.66 | 239.79 | +44.13 | +22.55% | +22.55% |
| 2020 | 104.08 | 195.66 | +91.58 | +87.99% | +87.99% |
| 2019 | 87.55 | 104.08 | +16.53 | +18.88% | +18.88% |
| 2018 | 40.60 | 87.55 | +46.95 | +115.64% | +115.64% |
| 2017 | 27.10 | 40.60 | +13.50 | +49.82% | +49.82% |
| 2016 | 27.85 | 27.10 | -0.75 | -2.69% | -2.69% |
| 2015 | 33.76 | 27.85 | -5.91 | -17.51% | -17.51% |
| 2014 | 29.24 | 33.76 | +4.52 | +15.46% | +15.46% |
| 2013 | 18.31 | 29.24 | +10.93 | +59.69% | +59.69% |
| 2012 | 20.99 | 18.31 | -2.68 | -12.77% | -12.77% |
| 2011 | 15.14 | 20.99 | +5.85 | +38.64% | +38.64% |
| 2010 | 6.77 | 15.14 | +8.37 | +123.63% | +123.63% |
| 2009 | 18.00 | 6.77 | -11.23 | -62.39% | -62.39% |
| 2008 | 15.96 | 18.00 | +2.04 | +12.78% | +12.78% |
Quarterly Price: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 149 | -31.1% | -52.6% |
| Q1 2026 | 216 | -25.2% | -18.5% |
| Q4 2025 | 289 | -11.7% | +8.6% |
| Q3 2025 | 327 | +4.1% | +36.8% |
| Q2 2025 | 314 | +18.6% | +55.7% |
| Q1 2025 | 265 | -0.3% | +60.0% |
| Q4 2024 | 266 | +11.2% | +21.1% |
| Q3 2024 | 239 | +18.4% | +50.0% |
| Q2 2024 | 202 | +21.9% | -30.0% |
| Q1 2024 | 166 | -24.6% | -46.8% |
| Q4 2023 | 219 | +37.8% | -25.6% |
| Q3 2023 | 159 | -44.8% | -30.9% |
| Q2 2023 | 288 | -7.4% | +26.6% |
| Q1 2023 | 311 | +5.5% | +19.4% |
| Q4 2022 | 295 | +28.0% | +10.9% |
| Q3 2022 | 231 | +1.3% | -17.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy